TON - March 2017, Vol 10, No 2

The endocrine therapy landscape has evolved from tamoxifen and aromatase inhibitors to CDK4/6 inhibitors and mTOR inhibitors. Read More ›

Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer has classified shift work as a possible carcinogen. Read More ›

Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer. Read More ›

Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS). Read More ›

Daily moderate physical activity can improve outcomes in patients with metastatic colorectal cancer (CRC). Read More ›

Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening. Read More ›

With an estimated 15.5 million cancer survivors living in the United States, there is an increased recognition of the need for continuing education of healthcare providers focused on this growing population. Read More ›

As a result of differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts. Read More ›

Survivors of lower gastrointestinal cancers can successfully use Internet-based patient-reported outcomes tools to report late- and long-term effects of their cancer. Read More ›

• Venetoclax plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
• Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer

Read More ›